Cytomegalovirus is the most common viral infection after transplantation. CMV infection causes significant morbidity and mortality in immunosuppressed solid organ and stem cell transplant recipients. Cytotect CP(R) Biotest contains specific antibodies that neutralize CMV. As such, it is used in those highly immunosuppressed patients to protect them from the detrimental effects of this virus. Additionally, it was described that Cytotect CP(R) Biotest can have immunomodulatory properties, e.g. by reducing organ rejection, potentially by inhibiting overshooting immune responses in the inflammatory milieu of transplant patients. A new scientific publication by Deml and colleagues indicates that Biotest's CMV hyperimmunoglobulin product Cytotect CP(R) Biotest has various beneficial effects on patients suffering from CMV infection. The study, which was supported by Biotest AG, analysed CMV-positive and CMV-negative blood donors and their immune response towards CMV. The new data shows that Cytotect CP(R) Biotest is able to activate different immune cells. This includes also the activation of cytotoxic T lymphocytes by CMV, which may happen via an immunological process termed cross-presentation. In this study, the effect was more prominent when Cytotect CP(R) Biotest was used and - importantly - this was also observed in presence of immunosuppressive drugs, which are part of the standard treatment regimen of patients after transplantation.